Latest news with #NicotineReplacementTherapy
Business Standard
24-07-2025
- Business
- Business Standard
Dr Reddys Lab gains after Q1 PAT jumps 2% YoY to Rs 1,418 cr
Dr Reddys Laboratories added 2.52% to Rs 1,279.05 after the company's consolidated net profit rose 1.8% to Rs 1,418.10 crore on 11.4% increase in revenue from operations to Rs 8,545.20 crore in Q1 FY26 over Q1 FY25. Profit before tax (PBT) stood at Rs 1,905 crore in Q1 FY26, up 1.2% YoY EBITDA for the quarter stood at Rs 2,278.4 crore, up 5.49% YoY. In its global generics business, North America contributed Rs 3,412.3 crore in revenue, a 11% year-on-year decline. Revenue from Europe surged 142% to Rs 1,274.4 crore, The India business generated revenue of Rs 1,471.1 crore, registering an 11% YoY. Revenue from Pharmaceutical Services and Active Ingredients (PSAI) came in at Rs 818.1 crore, a 7% YoY increase. Co-Chairman & MD, G V Prasad, said: "We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio. The pricing pressure on Lenalidomide is expected to intensify in the U.S. generics market. We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development." Hyderabad-based Dr. Reddys Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.
Hans India
24-07-2025
- Business
- Hans India
Dr Reddy's net up at Rs 1,410 cr in June qtr
Hyderabad: Dr Reddy's Laboratories on Wednesday reported a 1 per cent increase in consolidated net profit to Rs1,410 crore during the June quarter. The Hyderabad-based drug major reported a net profit of Rs 1,392 crore in the year-ago period. Revenue increased to Rs8,545 crore in he period under review from Rs 7,673 crore a year earlier. "We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio," Dr Reddy's Co-Chairman & MD G V Prasad said. The pricing pressure on Lenalidomide is expected to intensify in the US generics market, he noted. "We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development," Prasad said. Shares of the company ended 0.58 per cent up at Rs1,247.55 apiece on the BSE.
Economic Times
24-07-2025
- Business
- Economic Times
Dr. Reddy's Laboratories shares in focus as Q1 net profit jumps 2% YoY. Should you invest?
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Shares of Dr. Reddy's Laboratories are likely to be closely tracked on Thursday, July 24, after the pharmaceutical giant posted a marginal 2% year-on-year (YoY) increase in consolidated net profit to Rs 1,418 crore for the first quarter ended June. The modest profit growth comes despite a challenging pricing environment in the generics company's revenue from operations stood at Rs 8,545 crore, registering a healthy 11% YoY growth. However, on a sequential basis, net profit declined by 11% and revenue remained revenue growth during the quarter was broad-based and supported by strong contributions from the recently acquired consumer healthcare portfolio in Nicotine Replacement Therapy (NRT), as well as sustained momentum in branded rose 5% YoY to Rs 2,280 crore during the reporting quarter. Nevertheless, operating margins took a hit, declining 530 basis points to 56.9%. The margin compression was attributed to heightened price erosion in the generics segment and reduced operating leverage. A favourable product mix partly offset the company reported its Q1 results, domestic brokerage firm Nuvama has maintained a 'buy' rating on Dr. Reddy's Laboratories with a target price of Rs 1, the company's quarterly results fell short of expectations, Nuvama noted that new growth drivers are emerging. Progress on semaglutide in Canada remains on track, and the company is planning to file for abatacept in the US.A key positive surprise came from the Contract Development and Manufacturing Organization (CDMO) business, which is expected to contribute $100 million in FY26 and is targeting $300 million by FY30, Nuvama the management has reaffirmed its 25% margin guidance, supported by ongoing cost optimization efforts.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Time of India
24-07-2025
- Business
- Time of India
Dr. Reddy's Laboratories shares in focus as Q1 net profit jumps 2% YoY. Should you invest?
Shares of Dr. Reddy's Laboratories are likely to be closely tracked on Thursday, July 24, after the pharmaceutical giant posted a marginal 2% year-on-year (YoY) increase in consolidated net profit to Rs 1,418 crore for the first quarter ended June. The modest profit growth comes despite a challenging pricing environment in the generics segment. The company's revenue from operations stood at Rs 8,545 crore, registering a healthy 11% YoY growth. However, on a sequential basis, net profit declined by 11% and revenue remained flat. Explore courses from Top Institutes in Please select course: Select a Course Category Artificial Intelligence Healthcare healthcare Project Management MCA Operations Management Data Science CXO Degree Data Science Public Policy MBA others Others Leadership Management Finance PGDM Digital Marketing Data Analytics Design Thinking Product Management Technology Skills you'll gain: Duration: 7 Months S P Jain Institute of Management and Research CERT-SPJIMR Exec Cert Prog in AI for Biz India Starts on undefined Get Details The revenue growth during the quarter was broad-based and supported by strong contributions from the recently acquired consumer healthcare portfolio in Nicotine Replacement Therapy (NRT), as well as sustained momentum in branded markets. EBITDA rose 5% YoY to Rs 2,280 crore during the reporting quarter. Nevertheless, operating margins took a hit, declining 530 basis points to 56.9%. The margin compression was attributed to heightened price erosion in the generics segment and reduced operating leverage. A favourable product mix partly offset this. After the company reported its Q1 results, domestic brokerage firm Nuvama has maintained a 'buy' rating on Dr. Reddy's Laboratories with a target price of Rs 1,486. Live Events While the company's quarterly results fell short of expectations, Nuvama noted that new growth drivers are emerging. Progress on semaglutide in Canada remains on track, and the company is planning to file for abatacept in the US. A key positive surprise came from the Contract Development and Manufacturing Organization (CDMO) business, which is expected to contribute $100 million in FY26 and is targeting $300 million by FY30, Nuvama added. Additionally, the management has reaffirmed its 25% margin guidance, supported by ongoing cost optimization efforts. Also read: Mukul Agrawal adds 7 new stocks to portfolio; picks include recently listed stock. Check details ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
&w=3840&q=100)
Business Standard
23-07-2025
- Business
- Business Standard
Dr Reddy's Q1 result: Net profit up 2%, revenue hits record ₹8,545 crore
Hyderabad-based pharma major Dr Reddy's Laboratories (DRL) posted a consolidated net profit of ₹1,417 crore in the first quarter of financial year 2026 (Q1 FY26), a 2 per cent rise from ₹1,392 crore a year ago. The company clocked its highest-ever quarterly revenue at ₹8,545 crore, up 11 per cent year-on-year (Y-o-Y) from ₹7,672 crore. The increase in profit and revenue was attributed to new product launches and price hikes during the quarter. Sequentially, revenue was flat, with a marginal 0.4 per cent rise, while net profit declined by 11 per cent. G V Prasad, co-chairman and managing director, DRL, said: 'We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio.' Dr Reddy's is planning a major global rollout of semaglutide beginning in 2026, targeting 87 countries—including India, Brazil, Canada, and Turkey—subject to local patent expiries. In countries without active patents, launches will begin earlier. In India and Brazil, where the patent expires in March 2026, the company is targeting Day 1 launches. Erez Israeli, chief executive officer, DRL, said: 'The semaglutide launch is very important to us. It reflects our focus on business development, resource optimisation, and cost alignment for future growth. While there are execution risks, I'm confident we'll overcome them and continue our growth trajectory. Our pipeline includes 26 peptide-based GLP-1 products, expected to launch over the next decade.' Despite ongoing litigation with Novo Nordisk in India regarding the validity of the semaglutide patent, Dr Reddy's does not anticipate any delays or disruptions to its commercialisation plans. The company expects significant topline contribution from semaglutide, citing growing global demand for GLP-1 therapies in diabetes and weight management. Priced lower than Novo's offering (₹17,000 per month), Dr Reddy's plans to use its integrated manufacturing to enhance accessibility. Semaglutide is the first of 26 GLP-1 peptide-based drugs the company plans to launch globally over the next decade, with timing based on regional IP clearance. Dr Reddy's has guided for capital expenditure of approximately ₹2,700 crore in FY26, with major investments toward expanding peptide and biosimilar capacity in line with product-specific requirements. Segment Performance Global Generics: Revenue stood at ₹8,060 crore, up 10 per cent Y-o-Y, supported by new launches and stable volumes. North America: Revenue was ₹3,412 crore, down 11 per cent Y-o-Y due to price erosion in key products like Lenalidomide. The company launched five new products and filed one ANDA with the USFDA. As of June 2025, 73 filings are pending, including 70 ANDAs (43 Para IVs, 22 with potential First-to-File status) and three NDAs. Europe: Revenue surged 142 per cent Y-o-Y to ₹1,274 crore, driven by the NRT acquisition. The NRT business contributed ₹670 crore. Germany reported ₹320 crore (up 13 per cent), the UK ₹170 crore (up 10 per cent), and the rest of Europe ₹120 crore (up 30 per cent). Growth was led by new launches and forex gains, partly offset by price erosion. Thirteen new products were launched. Emerging Markets: Revenue rose 18 per cent Y-o-Y to ₹1,404 crore. Russia contributed ₹710 crore (up 28 per cent), the Commonwealth of Independent States and Romania ₹200 crore (up 2 per cent), and the rest of world territories ₹500 crore (up 13 per cent). A total of 26 new products were launched across these regions. Pharmaceutical Services and Active Ingredients: Revenue rose 7 per cent Y-o-Y to ₹818 crore, supported by new API launches, forex gains, and pharmaceutical services expansion. The company filed 12 Drug Master Files globally during the quarter. The results were announced post market hours. Dr Reddy's shares rose 0.58 per cent, closing at ₹1,247.50 apiece on the BSE.
